Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-10-28

Clinical Trial Update: Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants [Phase 1]

View source ↗

Summary

A Phase 1 study assessed safety, tolerability, and pharmacokinetics of BG00010 (Neublastin) in participants with sciatica; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BG00010 (Neublastin) (BG00010)

Snippet

Sponsor: Biogen | Conditions: Sciatica | Phase 1 | Status: COMPLETED